The underlying issue is the lumpiness of cash receipts.
Q1FY23 had approximately $12M cash receipts which resulted in around -$0.5M in operating cashflow. Q1FY24 has only $6.4M cash receipts, resulting in -$8M operating cashflow. Huge difference and shows the extent of lumpiness.
While I like to think they run a tight ship, the fact that they had to meet up with institutions to get firm commitments for $5M of the $6M means the word is already out on the street, as evident by the recent selling volumes. Not sure what the company can do about this even though they might run a tight ship internally. Retail investors like us are at the bottom of chain.
The one question I have in mind is the cost of equity relative to cost of debt (including convertible bonds). If the problems are temporarily and the share price is undervalued, surely there are better options than further dilution at a significant discount.
- Forums
- ASX - By Stock
- ALC
- Ann: Trading Halt
Ann: Trading Halt, page-50
Featured News
Add ALC (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $75.20M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 5.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.7¢ | 65332 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 56958 | 0.056 |
2 | 225000 | 0.055 |
2 | 134259 | 0.054 |
3 | 446425 | 0.053 |
8 | 1020323 | 0.052 |
Price($) | Vol. | No. |
---|---|---|
0.057 | 50760 | 3 |
0.058 | 101740 | 2 |
0.059 | 160032 | 4 |
0.060 | 912710 | 8 |
0.061 | 66190 | 2 |
Last trade - 08.51am 12/11/2024 (20 minute delay) ? |
Featured News
ALC (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online